Serum cystatin C predicts vancomycin trough levels better than serum creatinine in hospitalized patients: A cohort study

Erin N. Frazee, Andrew D Rule, Sandra Herrmann, Kianoush B. Kashani, Nelson Leung, Abinash Virk, Nikolay Voskoboev, John C Lieske

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Introduction: Serum cystatin C can improve glomerular filtration rate (GFR) estimation over creatinine alone, but whether this translates into clinically relevant improvements in drug dosing is unclear.Methods: This prospective cohort study enrolled adults receiving scheduled intravenous vancomycin while hospitalized at the Mayo Clinic in 2012. Vancomycin dosing was based on weight, serum creatinine with the Cockcroft-Gault equation, and clinical judgment. Cystatin C was later assayed from the stored serum used for the creatinine-based dosing. Vancomycin trough prediction models were developed by using factors available at therapy initiation. Residuals from each model were used to predict the proportion of patients who would have achieved the target trough with the model compared with that observed with usual care.Results: Of 173 patients enrolled, only 35 (20%) had a trough vancomycin level within their target range (10 to 15 mg/L or 15 to 20 mg/L). Cystatin C-inclusive models better predicted vancomycin troughs than models based upon serum creatinine alone, although both were an improvement over usual care. The optimal model used estimated GFR by the Chronic Kidney Disease Epidemiology Collaborative (CKD-EPI) creatinine-cystatin C equation (R2 = 0.580). This model is expected to yield 54% (95% confidence interval 45% to 61%) target trough attainment (P <0.001 compared with the 20% with usual care).Conclusions: Vancomycin dosing based on standard care with Cockcroft-Gault creatinine clearance yielded poor trough achievement. The developed dosing model with estimated GFR from CKD-EPIcreatinine-cystatin C could yield a 2.5-fold increase in target trough achievement compared with current clinical practice. Although this study is promising, prospective validation of this or similar cystatin C-inclusive dosing models is warranted.

Original languageEnglish (US)
Article numberR110
JournalCritical Care
Volume18
Issue number3
DOIs
StatePublished - May 19 2014

Fingerprint

Cystatin C
Vancomycin
Creatinine
Cohort Studies
Serum
Glomerular Filtration Rate
Chronic Renal Insufficiency
Epidemiology
Prospective Studies
Confidence Intervals
Weights and Measures
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Critical Care and Intensive Care Medicine

Cite this

Serum cystatin C predicts vancomycin trough levels better than serum creatinine in hospitalized patients : A cohort study. / Frazee, Erin N.; Rule, Andrew D; Herrmann, Sandra; Kashani, Kianoush B.; Leung, Nelson; Virk, Abinash; Voskoboev, Nikolay; Lieske, John C.

In: Critical Care, Vol. 18, No. 3, R110, 19.05.2014.

Research output: Contribution to journalArticle

Frazee, Erin N. ; Rule, Andrew D ; Herrmann, Sandra ; Kashani, Kianoush B. ; Leung, Nelson ; Virk, Abinash ; Voskoboev, Nikolay ; Lieske, John C. / Serum cystatin C predicts vancomycin trough levels better than serum creatinine in hospitalized patients : A cohort study. In: Critical Care. 2014 ; Vol. 18, No. 3.
@article{56d42d97e2b241e799a4dee759c1669f,
title = "Serum cystatin C predicts vancomycin trough levels better than serum creatinine in hospitalized patients: A cohort study",
abstract = "Introduction: Serum cystatin C can improve glomerular filtration rate (GFR) estimation over creatinine alone, but whether this translates into clinically relevant improvements in drug dosing is unclear.Methods: This prospective cohort study enrolled adults receiving scheduled intravenous vancomycin while hospitalized at the Mayo Clinic in 2012. Vancomycin dosing was based on weight, serum creatinine with the Cockcroft-Gault equation, and clinical judgment. Cystatin C was later assayed from the stored serum used for the creatinine-based dosing. Vancomycin trough prediction models were developed by using factors available at therapy initiation. Residuals from each model were used to predict the proportion of patients who would have achieved the target trough with the model compared with that observed with usual care.Results: Of 173 patients enrolled, only 35 (20{\%}) had a trough vancomycin level within their target range (10 to 15 mg/L or 15 to 20 mg/L). Cystatin C-inclusive models better predicted vancomycin troughs than models based upon serum creatinine alone, although both were an improvement over usual care. The optimal model used estimated GFR by the Chronic Kidney Disease Epidemiology Collaborative (CKD-EPI) creatinine-cystatin C equation (R2 = 0.580). This model is expected to yield 54{\%} (95{\%} confidence interval 45{\%} to 61{\%}) target trough attainment (P <0.001 compared with the 20{\%} with usual care).Conclusions: Vancomycin dosing based on standard care with Cockcroft-Gault creatinine clearance yielded poor trough achievement. The developed dosing model with estimated GFR from CKD-EPIcreatinine-cystatin C could yield a 2.5-fold increase in target trough achievement compared with current clinical practice. Although this study is promising, prospective validation of this or similar cystatin C-inclusive dosing models is warranted.",
author = "Frazee, {Erin N.} and Rule, {Andrew D} and Sandra Herrmann and Kashani, {Kianoush B.} and Nelson Leung and Abinash Virk and Nikolay Voskoboev and Lieske, {John C}",
year = "2014",
month = "5",
day = "19",
doi = "10.1186/cc13899",
language = "English (US)",
volume = "18",
journal = "Critical Care",
issn = "1364-8535",
publisher = "BioMed Central Ltd.",
number = "3",

}

TY - JOUR

T1 - Serum cystatin C predicts vancomycin trough levels better than serum creatinine in hospitalized patients

T2 - A cohort study

AU - Frazee, Erin N.

AU - Rule, Andrew D

AU - Herrmann, Sandra

AU - Kashani, Kianoush B.

AU - Leung, Nelson

AU - Virk, Abinash

AU - Voskoboev, Nikolay

AU - Lieske, John C

PY - 2014/5/19

Y1 - 2014/5/19

N2 - Introduction: Serum cystatin C can improve glomerular filtration rate (GFR) estimation over creatinine alone, but whether this translates into clinically relevant improvements in drug dosing is unclear.Methods: This prospective cohort study enrolled adults receiving scheduled intravenous vancomycin while hospitalized at the Mayo Clinic in 2012. Vancomycin dosing was based on weight, serum creatinine with the Cockcroft-Gault equation, and clinical judgment. Cystatin C was later assayed from the stored serum used for the creatinine-based dosing. Vancomycin trough prediction models were developed by using factors available at therapy initiation. Residuals from each model were used to predict the proportion of patients who would have achieved the target trough with the model compared with that observed with usual care.Results: Of 173 patients enrolled, only 35 (20%) had a trough vancomycin level within their target range (10 to 15 mg/L or 15 to 20 mg/L). Cystatin C-inclusive models better predicted vancomycin troughs than models based upon serum creatinine alone, although both were an improvement over usual care. The optimal model used estimated GFR by the Chronic Kidney Disease Epidemiology Collaborative (CKD-EPI) creatinine-cystatin C equation (R2 = 0.580). This model is expected to yield 54% (95% confidence interval 45% to 61%) target trough attainment (P <0.001 compared with the 20% with usual care).Conclusions: Vancomycin dosing based on standard care with Cockcroft-Gault creatinine clearance yielded poor trough achievement. The developed dosing model with estimated GFR from CKD-EPIcreatinine-cystatin C could yield a 2.5-fold increase in target trough achievement compared with current clinical practice. Although this study is promising, prospective validation of this or similar cystatin C-inclusive dosing models is warranted.

AB - Introduction: Serum cystatin C can improve glomerular filtration rate (GFR) estimation over creatinine alone, but whether this translates into clinically relevant improvements in drug dosing is unclear.Methods: This prospective cohort study enrolled adults receiving scheduled intravenous vancomycin while hospitalized at the Mayo Clinic in 2012. Vancomycin dosing was based on weight, serum creatinine with the Cockcroft-Gault equation, and clinical judgment. Cystatin C was later assayed from the stored serum used for the creatinine-based dosing. Vancomycin trough prediction models were developed by using factors available at therapy initiation. Residuals from each model were used to predict the proportion of patients who would have achieved the target trough with the model compared with that observed with usual care.Results: Of 173 patients enrolled, only 35 (20%) had a trough vancomycin level within their target range (10 to 15 mg/L or 15 to 20 mg/L). Cystatin C-inclusive models better predicted vancomycin troughs than models based upon serum creatinine alone, although both were an improvement over usual care. The optimal model used estimated GFR by the Chronic Kidney Disease Epidemiology Collaborative (CKD-EPI) creatinine-cystatin C equation (R2 = 0.580). This model is expected to yield 54% (95% confidence interval 45% to 61%) target trough attainment (P <0.001 compared with the 20% with usual care).Conclusions: Vancomycin dosing based on standard care with Cockcroft-Gault creatinine clearance yielded poor trough achievement. The developed dosing model with estimated GFR from CKD-EPIcreatinine-cystatin C could yield a 2.5-fold increase in target trough achievement compared with current clinical practice. Although this study is promising, prospective validation of this or similar cystatin C-inclusive dosing models is warranted.

UR - http://www.scopus.com/inward/record.url?scp=84903643749&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84903643749&partnerID=8YFLogxK

U2 - 10.1186/cc13899

DO - 10.1186/cc13899

M3 - Article

C2 - 24887089

AN - SCOPUS:84903643749

VL - 18

JO - Critical Care

JF - Critical Care

SN - 1364-8535

IS - 3

M1 - R110

ER -